Anti-Epileptic Drugs Market Report 2022: Increasing Awareness About Treatment With Anti-Epileptic Drugs, Patent Expiration and Approval of Pipeline Products to Drive Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Anti-epileptic Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.

The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl - GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2021-2025 for each segment.

Based on geographical demarcation, the report provides analysis of following geographical segments along with major countries:

• North America
• Canada
• United States
• Europe
• Germany
• United Kingdom
• Rest of Europe
• Asia Pacific
• Japan
• China
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter's five forces along with competitive landscape analysis are also incorporated in this report.

Based on the Drug Class, global anti-epileptic drugs market is segmented as follows:

• Hydantoin derivatives
• Iminostilbenes
• Long acting barbiturates
• Succinimides
• Benzodiazepines
• Carbonic anhydrase inhibitors (CAI)
• GAMA- vinyl - GABA
• Amino acid derivatives
• Monosaccharide derivatives
• Others
• Valproic acid derivatives
• Deoxy barbiturate
• Phenyltriazine
• Nicotinic acid derivatives
• Sulphonamide derivatives

   

Increasing awareness about treatment with anti-epileptic drugs, patent expiration and approval of pipeline products are the factors responsible for the market growth. The global anti-epileptic drugs market is emerging at considerable pace because of high prevalence of epilepsy and more research and development activities.

Geographically, the global anti-epileptic drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

2.1. Global Anti-epileptic Drugs Market Portraiture

2.1.1. Global Anti-epileptic Drugs Market, by Drug Class, 2020 (US$ Mn)

2.1.2. Global Anti-epileptic Drugs Market, by Geography, 2020 (US$ Mn)

Chapter 3. Anti-epileptic Drugs: Market Dynamics and Outlook

3.1. Market Definition and Overview

3.2. Epilepsy: Epidemiology

3.3. Drivers

3.4. Challenges

3.5. Opportunities

3.6. Attractive Investment Proposition, by Geography, 2020

3.7. Value Chain Analysis

3.8. Major Agreements, Partnerships and Collaborations

3.9. Competitive Landscape

3.9.1. Competitive Landscape, by Key Players, 2020

Chapter 4. Global Anti-epileptic Drugs Market, by Drug Class, 2019-2029 (US$ Mn)

4.1. Overview

4.1.1. Attractive Investment Proposition, by Drug Class, 2020

4.2. Hydantoin derivatives

4.2.1. Phenytoin

4.2.2. Fosphenytoin

4.3. Iminostilbenes

4.3.1. Carbamazepine

4.3.2. Oxcarbazepine

4.4. Long acting barbiturates

4.4.1. Phenobarbitone

4.4.2. Methobarbitone

4.5. Succinimides

4.5.1. Ethosuximide

4.5.2. Methsuximide

4.5.3. Phensuximide

4.6. Benzodiazepines

4.6.1. Clonazepam

4.6.2. Nitrazepam

4.6.3. Diazepam

4.7. Carbonic anhydrase inhibitors (CAI)

4.7.1. Acetazolamide

4.7.2. Sulthiame

4.8. GAMA- vinyl - GABA

4.8.1. Vigabatrin

4.9. Amino acid derivatives

4.9.1. GABA pentin

4.10. Monosaccharide derivatives

4.10.1. Topiramate

4.11. Others (Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives and Sulphonamide derivatives)

4.12. Phase III (Market estimations by 2029)

4.12.1. Brivaracetam or ucb 34714 (UCB Pharma)

4.12.2. Topiramate (Janssen Research & Development, LLC)

4.12.3. Levetiracetam (Janssen Research & Development, LLC)

4.12.4. Others

4.13. Tabular Presentation of Phase II (Qualitative Information)

4.14. Tabular Presentation of Phase Phase I (Qualitative Information)

Chapter 5. Global Anti-epileptic Drugs Market, by Geography, 2019 - 2029 (US$ Mn)

Chapter 6. Company Profiles

6.1. Abide Therapeutics

6.1.1. Business Description

6.1.2. Financial Information (Subject to data availability)

6.1.3. Application Portfolio

6.1.4. Key Developments

6.2. Advicenne Pharma SA

6.3. Alexza Pharmaceuticals

6.4. Argentum Pharmaceuticals

6.5. GlaxoSmithKline (GSK) plc

6.6. GW Pharmaceuticals Plc

6.7. Janssen Pharmaceuticals

6.8. Marinus Pharmaceuticals

6.9. Novartis Pharmaceuticals Corp

6.10. Otsuka Pharmaceuticals

6.11. Pfizer Inc.

6.12. Takeda Pharmaceutical Company Ltd

Companies Mentioned

• Abide Therapeutics
• Advicenne Pharma SA
• Alexza Pharmaceuticals
• Argentum Pharmaceuticals
• GlaxoSmithKline (GSK) plc
• GW Pharmaceuticals
• Janssen Pharmaceuticals
• Marinus Pharmaceuticals
• Novartis Pharmaceuticals Corp
• Otsuka Pharmaceu

For more information about this report visit https://www.researchandmarkets.com/r/waisgy

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900